These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 27067333)

  • 1. Population Pharmacokinetics Analysis To Inform Efavirenz Dosing Recommendations in Pediatric HIV Patients Aged 3 Months to 3 Years.
    Luo M; Chapel S; Sevinsky H; Savant I; Cirincione B; Bertz R; Roy A
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3676-86. PubMed ID: 27067333
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetic Model Linking Plasma and Peripheral Blood Mononuclear Cell Concentrations of Efavirenz and Its Metabolite, 8-Hydroxy-Efavirenz, in HIV Patients.
    Habtewold A; Aklillu E; Makonnen E; Yimer G; Bertilsson L; Burhenne J; Owen JS
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559276
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of CYP2B6 516G>T polymorphism and interoccasion variability (IOV) on the population pharmacokinetics of efavirenz in HIV-infected South African children.
    Viljoen M; Karlsson MO; Meyers TM; Gous H; Dandara C; Rheeders M
    Eur J Clin Pharmacol; 2012 Apr; 68(4):339-47. PubMed ID: 22057858
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CYP2B6 Haplotype Predicts Efavirenz Plasma Concentration in Black South African HIV-1-Infected Children: A Longitudinal Pediatric Pharmacogenomic Study.
    Reay R; Dandara C; Viljoen M; Rheeders M
    OMICS; 2017 Aug; 21(8):465-473. PubMed ID: 28816644
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of CYP2B6 Gene Polymorphisms on Efavirenz Plasma Concentrations in Chinese Patients with HIV Infection.
    Meng X; Yin K; Wang J; Dong P; Liu L; Shen Y; Shen L; Ma Q; Lu H; Cai W
    PLoS One; 2015; 10(6):e0130583. PubMed ID: 26107645
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and non-genetic factors influencing efavirenz population pharmacokinetics among human immunodeficiency virus-1-infected children in Ethiopia.
    Chala A; Kitabi EN; Ahmed JH; Tadesse BT; Chaka TE; Makonnen E; Aklillu E
    CPT Pharmacometrics Syst Pharmacol; 2023 Jun; 12(6):783-794. PubMed ID: 36840416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic-based efavirenz dose modification: suggestions for an African population and the different CYP2B6 genotypes.
    Mukonzo JK; Owen JS; Ogwal-Okeng J; Kuteesa RB; Nanzigu S; Sewankambo N; Thabane L; Gustafsson LL; Ross C; Aklillu E
    PLoS One; 2014; 9(1):e86919. PubMed ID: 24497997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic-Pharmacogenetic Model of HIV-infected Patients in Thailand.
    Chaivichacharn P; Avihingsanon A; Manosuthi W; Ubolyam S; Tongkobpetch S; Shotelersuk V; Punyawudho B
    Clin Ther; 2020 Jul; 42(7):1234-1245. PubMed ID: 32451120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenetics of plasma efavirenz exposure in HIV-infected adults and children in South Africa.
    Sinxadi PZ; Leger PD; McIlleron HM; Smith PJ; Dave JA; Levitt NS; Maartens G; Haas DW
    Br J Clin Pharmacol; 2015 Jul; 80(1):146-56. PubMed ID: 25611810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Plasma efavirenz concentrations and the association with CYP2B6-516G >T polymorphism in HIV-infected Thai children.
    Puthanakit T; Tanpaiboon P; Aurpibul L; Cressey TR; Sirisanthana V
    Antivir Ther; 2009; 14(3):315-20. PubMed ID: 19474465
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Secondary metabolism pathway polymorphisms and plasma efavirenz concentrations in HIV-infected adults with CYP2B6 slow metabolizer genotypes.
    Haas DW; Kwara A; Richardson DM; Baker P; Papageorgiou I; Acosta EP; Morse GD; Court MH
    J Antimicrob Chemother; 2014 Aug; 69(8):2175-82. PubMed ID: 24729586
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CYP2B6 genotype-directed dosing is required for optimal efavirenz exposure in children 3-36 months with HIV infection.
    Bolton Moore C; Capparelli EV; Samson P; Bwakura-Dangarembizi M; Jean-Philippe P; Worrell C; Heckman B; Purdue L; Spector SA; Benns A; Borkowsky W; Loftis A; Hawkins E; Wallis C; Chadwick EG;
    AIDS; 2017 May; 31(8):1129-1136. PubMed ID: 28323755
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genetic variants in CYP2B6 and CYP2A6 explain interindividual variation in efavirenz plasma concentrations of HIV-infected children with diverse ethnic origin.
    Soeria-Atmadja S; Österberg E; Gustafsson LL; Dahl ML; Eriksen J; Rubin J; Navér L
    PLoS One; 2017; 12(9):e0181316. PubMed ID: 28886044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis.
    Gengiah TN; Holford NH; Botha JH; Gray AL; Naidoo K; Abdool Karim SS
    Eur J Clin Pharmacol; 2012 May; 68(5):689-95. PubMed ID: 22108776
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CYP2B6 genotype is a strong predictor of systemic exposure to efavirenz in HIV-infected Zimbabweans.
    Maimbo M; Kiyotani K; Mushiroda T; Masimirembwa C; Nakamura Y
    Eur J Clin Pharmacol; 2012 Mar; 68(3):267-71. PubMed ID: 21901344
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic/pharmacogenetic model for optimization of efavirenz therapy in Caucasian HIV-infected patients.
    Sánchez A; Cabrera S; Santos D; Valverde MP; Fuertes A; Domínguez-Gil A; García MJ;
    Antimicrob Agents Chemother; 2011 Nov; 55(11):5314-24. PubMed ID: 21896912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic and Pharmacodynamic Comparison of Once-Daily Efavirenz (400 mg vs. 600 mg) in Treatment-Naïve HIV-Infected Patients: Results of the ENCORE1 Study.
    Dickinson L; Amin J; Else L; Boffito M; Egan D; Owen A; Khoo S; Back D; Orrell C; Clarke A; Losso M; Phanuphak P; Carey D; Cooper DA; Emery S; Puls R;
    Clin Pharmacol Ther; 2015 Oct; 98(4):406-16. PubMed ID: 26044067
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients.
    Elens L; Vandercam B; Yombi JC; Lison D; Wallemacq P; Haufroid V
    Pharmacogenomics; 2010 Sep; 11(9):1223-34. PubMed ID: 20860463
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efavirenz pharmacokinetics in HIV-1-infected children are associated with CYP2B6-G516T polymorphism.
    Saitoh A; Fletcher CV; Brundage R; Alvero C; Fenton T; Hsia K; Spector SA
    J Acquir Immune Defic Syndr; 2007 Jul; 45(3):280-5. PubMed ID: 17356468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Is the recommended once-daily dose of lamivudine optimal in West African HIV-infected children?
    Bouazza N; Hirt D; Bardin C; Diagbouga S; Nacro B; Hien H; Zoure E; Rouet F; Ouiminga A; Blanche S; Van De Perre P; Tréluyer JM; Msellati P; Urien S
    Antimicrob Agents Chemother; 2010 Aug; 54(8):3280-6. PubMed ID: 20516271
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.